Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the completion of a $60 million financing.
Researchers say they have removed HIV from the DNA of mice, an achievement the scientists say could be an early step toward an elusive cure for humans.
